11

2

The presentation and the information it contains do not constitute an offer to sell or subscribe for on the solicitation of an offer to buy or subscribefor securities in any country. This presentation should not be used as a basis for the purchase of shares in IntegraGen (the “Company”). Thedistribution of this presentation may be against the law in some countries.

The securities described in this presentation have not been and will not be registered under the U.S. Securities act of 1933 as amended (the “USSecurities Act”) and therefore cannot be offered or sold in the U.S. unless exempted from the registration requirements of the U.S. Securities Act. Anypublic securities offer in the U.S. will be carried out through a prospectus available from the Company containing detailed information about theCompany, its management Team, and its financial statements. The Company does not intend to register any, or all of this securities offered in theU.S. or to make a public securities offer in the U.S.

The Company shall not be held liable for any losses or damages resulting from the use of this document or the information it contains. The Companydoes not make any express or implied guarantee that the information contained in this document is free from errors or omissions. None of theinformation contained in this document should be considered as a commitment or a guarantee provided by the Company.

This documents contents forward-looking statements and comments about the Company’s strategy and objectives. The Company may not be able toreach these objectives and the Company is under no obligation to update the forward-looking statements. Actual results may differ materially fromthose expressed or implied in the forward-looking statements. The forward looking statements involve inherent uncertainties and are subject tonumerous risk factors such as those described in the Company’s registration document. Past performance is not an indication of future performanceand persons in need of advice should contact an independent financial advisor

3

Blood Tissue

Nucleic acid

4

Agreement with APHP

Initial quotation of ALINT in2010, Public offering onAlternext in 2014

2016 Revenues : €6 m

HQ in Evry’s Genopole, officesin Paris & Cambridge (Mass, US)

38 employees

Bernard Courtieu, DVM, MDA – CEO Previously Cap Gemini Consulting, VP Life Sciences – France, and Ariba, Head of French Operations

Laurence Riot-Lamotte

CFO

Emmanuel Martin, R.Ph.VP, IntegraGen Genomics

Francis Rousseau, PhD Head of Genomics Operations

Bérengère GeninHead of Bio-IT

Institut Pasteur sequencing

platform

1st clinical sequencing

platform in EU

Launch of ARISk® Test

in USA

First oncology biomarker

patent

NGS

sequencing

Genomic services platform

Company founded in Evry, France

Larry Yost, RPhGM, IntegraGen Inc.

5

IntegraGen Confidential

Exec Committee Members

CEO

Office Manager

US headVP US Operations

CFO

3p

BU Genomics

BU head

VP Genomic Services

GECO

IT- Soft devpt

BD

2p

DEVELOPMENT

3p

8p

Bio-Info

BU Diagnostics

BU Head

VP Diagnostics

PROD.

1p

R & D

2p

BD AND M&S

1p

EVRY- Seq

EVRY- Gen

PASTEUR

VILLEJUIF

LABS

11p

Bioinfo & IT Director

COO - Q

GenomicsOperations,

Quality, Investment

maintenancereporting

6

Sequencing technologies, Largest French private provider,

Exome sequencing for clinical research ("clinical grade"),

Ct DNA sequencing / exome & mutational load from blood,

IT interfaces / bioIT team / Exome interpretation software,

Industrialization already demonstrated at Gustave Roussy & Institut Pasteur,

Specific, protected companion diagnostic biomarker (miRpredix-31-3p), CE marked Dx kit.

Backed by an internal Quality Management System

77

What makes IntegraGen Genomics unique ?

www.integragen-genomics.com

8

R&D centers (Academic, Pharma, AgVet, Biotech)

Cancerology centers, hospitals

Institut Pasteur

R&D centers

Data quality, speed, data support, analysis pipeline

Industrialization of process, speed of response, interface for biologist

(data viewer & dashboard)

Speed, specific implementation steps, dedicated LIMS

Digging into data sets, providing bio-IT expertise, specific pipelines

Genomics services –

High throughput

Sequencing

for clinical research

Sequencing in microbiology

Genomic consulting

The business unit dedicated to generating molecular information

9

Exome / Target seq Genome SNP Genotyping Pharmacogenetics Genome profiling

RNA-Seq Small RNA-Seq HT RT-Q PCR Digital gene expression

(Nanostring)

Meth arrays Illumina Methyl-Seq RRBS ChIP-SEQ

Study Design

New applications d

protocols set-up

Developments in

bioinformatics et

biostatistics

Online applications for

results navigation

(ERIS, OSCAR)

LIMS Development

Production platformset-up

Main LaboratoryGénopôle d’Evry

High Throughput Platform

Large Study Management & Production

Developments of new protocols and analysis

pipelinesSince March 2015

Plateforme IG

Institut Pasteur

High ThroughputRoutine Sequencingfor microbialstrains (CNR)

Since Mai 2014

Plateforme IG

Gustave Roussy

Exomes et RNASeqsequencing for

patients in clinicaltrials

10

Direct access to analyzed and pre-filtered results through graphical interface and intuitive filters

Quick check of known genes and hotspots

Open to external databases

Easy report generation

10

11

* CAGR : Compounded Average Growth Rate

2016 highlights

• Continued development of clinical & operated platforms +30% in 2016.

• Significant price pressure & erosion on R&D segment in 2015 impacting growth in value – stabilized in 2016.

• New partnership with APHP, with first revenues expected in 2017

• Extremely satisfied customers : “Thank you for this remarkable piece of work; we’re very pleased – just have to write the paper now and wished we had known you before” .

1.2

2.32.8

3.2

4.6 4.7 5.4 5.6

4.2 4.2 -

0,4

1,41.8

1

2

3

4

5

6

7

2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Genomics Revenues R&D segment

Clinical

R&D

in million €

12

The evolution of cost per base has not led to a reduction of total cost of genomic research, but to a similar increase in data production : the “Geno-Tsunami”

From 2005 to 2010, IntegraGen was providing mostly raw data

In 2010 IntegraGen launched its first genomic data viewer ERIS

ERIS allows sequencing services customers to view the genomic data and filter data from all types of queries

In 2013, IntegraGen launched OSCAR, the Online Screening tool for Cancer, with a clinically relevant interface, developed in conjunction with Gustave Roussy biologists & oncologists

In 2014 IntegraGen, Sogeti HT, Gustave Roussy & INSERM announced the launch of the ICE project – objective is to transform whole exome data into optimization of cancer treatment

13

2. Nucleic acidsreception

3. Librairies preparation

5. Bio-informatic analysis6. Variants selection

1. Sample prep

7. Variants validation & report editing

4. NGS NextSeq5002 patients/day

Tumor Board

1414

Beta test version in Q1 2017

“the development of targeted therapies and immunotherapies in thetreatment of solid tumors has significantly changed the management ofpatients with cancer”

ICE is Project to develop an advanced software program which supports interpretation of

exome and transcriptome data obtained from tumor and healthy tissue from patients.

optimize the diagnosis of cancer and provide data for identifying :

‒ genomic alterations which potentially predict response to drug therapies

‒ context information from public and premium content sources and potentially relevantclinical trials

‒ optimal treatment approaches

15

… stabilized …

• Exome, genome and panels now routinely used for close to a decade

… affordable …

• When compared to total cost of care, with pricesranging from '00s to '000s of euro per test

… clinically usefull…

• To orient patients towards targeted therapies, immunotherapies, …

… and cost effective

• Ct DNA – Liquid biopsies becoming new gold standard in tissue analysis.

Biologists

• Information required to be both available but also managedvia intelligible interface.

Cancer specialists / oncologists

• Liquid biopsies becoming new gold standard in tissue analysis .

• Usefull (actionable) information when deciding whichtherapy to use, which clintrials to orient patient to,

Patients

• Making sure treatment choices are made using the latestavailable options optimizing survival .

Payors

• Reducing unefficent therapies.

Sequencing technology is now… What it means for

Regulatory landscape is now the critical driver of clinical adoption in Europe

16

Leading private genomic lab in France

Key contributor to the Genomic 2025 French National Plan

Partner of the leading French institutions (G. Roussy, Pasteur, AP-HP, others tba)

Able to deliver timely high-qualiy analysis

Able to industrialize & implement"turnkey"solutions (GR live in 8 weeks, IP in 12)

Access to clinical use of results Onco panels (or exome)

Interpretation software

Access to other geographies to replicateGR/IP pilot model South Europe

Germany & East Europe

UK

Access to other geographies to replicateGR/IP pilot model South Europe

Germany & East Euro

1717

Diagnostics

www.integragen-genomics.com

1818

A few biomarkers in mCRC in the portfolio

miR-31-3p potential development in NSCLC

Partnershp with Big pharma to develop TKIspecific marker in NSCLC

Strategic decision NOT TO develop newmarkers on own funds, but to co-developmarkers with drug manufacturer

Single biomarker test RT-qPCR

Patented, co-owned by IntegraGen withexclusive licensing rights

Improve patient selection for anti-EGFRtherapies

‒ Increased ability to identify responderscompared to KRAS testing alone

Potential for rapid adoption

‒ Established screening program for KRAStesting

+ possible predictive utility in Lung Cancer

19

Metastatic Colorectal Cancer (mCRC) patients can be treated by:

Traditional surgery & Chemotherapy (FolFox, Folfiri, Folfirinox)

Targeted therapies

Anti VGF (Avastin® Roche)

Anti-EGFR (Erbitux® Merck-Lilly; Vectibix® Amgen)

Choice of targeted therapy varies across geographies, but consensus considers

Avastin is considered first treatment of choise in US &² Japan as it is not related to any biomarker prior to treatment

When only eligible patients (wild KRAS, c. 50% of population) can benefit from anti-EGFR patients will vary from low to high, with high variability of reponse and some side effects

Even though Half of the patients would be significantly better off if started with anti EGFR

Targeted population

US : 140,000 new cases of mCRC/year

Of which 50% are KRAs wild type (eligible for anti-EGFR treatment)

i.e. 70k to 140k patients in the target population

Western Europe : 170,000 new cases of mCRC (id)

Rest of world : 500,000 new cases

Business potential

US : 250 m$

West Europe : 250 m$

20

2011/2012 analysis of academic retrospective collections

2013-2015 analysis of prospectively gathered samples from randomized phase III trials

Initial discovery Replication studies

33 pts 99 pts

Platform presentation @ ESMO, 2 posters (2013) and published in Clinical Cancer Research

(2014)

“miR-31-3p seems to be a new mCRC biomarker whose expression allows for the identification of patients likely to respond to anti EGFR therapy”

NEW EPOC PICCOLO FIRE 3

272/ 158 460 / 188 592 / 370

2 ASCO posters & platform presentation (2013 / 2014)

Predictive biomarker of cetuximab effect

2 posters – ESMO (2014) and ASCO (2105)

Validation of role of biomarker

Chemo + Cetuximab

vs.

Chemo alone (FOLFOX)

Chemo + Pani.

vs.

Chemo alone (Irinotecan)

Chemo + Cetuximab

vs.

Chemo + Bevacizumab

(FOLFIRI)

Tota

l of

84

8 p

atie

nts

in 9

ind

epen

den

t co

ho

rts

* total # of patients (pts) in trial / # of patients RAS wild type analyzed

Abstract presented at plenary session ASCO

2016

Validation of threshold, predictive value and

clinical utility (in choice of 1st line therapy)

21

KRAs / all RAS wild : 50%

KRAS (40%) / all RAS (10%) mutated : 50%

BevacizumabCetuximab

Median OS

27.4 m [23.7 ; 32.4]

39.4 m [31.0 ; 52.0]

Low: miR-31-3p < cut-off (n = 245)

Median OS

20.1 m [14.5 ; 30.8]

20.3 m [14.7 ; 27.1]

BevacizumabCetuximab

High: miR-31-3p ≥ cut-off (n = 125)

12 Months difference at median OS for low expressors or miR-31-3p

Analysis of the FIRE-3 samples

Which targetted therapy to add to traditional Chimio

(Folfox/folfiri)

Avastin(only available option)

EitherAvastin / Erbitux

Erbitux(12 Months OS

advantage)

all RAS/KRAS mutated :

50%

miR-31-3p Low 34%

miR-31-3p high : 16%

all RAS/KRAS wild type

50%

What is the molecular status of a specific patient?

Metastatic colorectal cancer (mCRC)84,000 annually (US) - 170,000 (EU)

22

USA Europe

Licensing deal with CLIA lab

Clinical utility study (TBD) run at licensing partner’s lab

Reimbursement via Medicare and private payors

Incorporation into NCCN/ASCO guidelines

Design developmental deal with subcontractor/partner

Reference lab / distributors

RIHN guidelines – filed by HEGP on Sept 15

Certified CLIA lab On-going negociations withUS CLIA lab – term sheet

CE marked kit manufacturing

On-going negociations withreference labs

23

June-16 Sept-16 Oct-16

Process validation - Production of 3 batches

- Stability study- CE marking final dossier

Feb-17 Jun-17

17/01/17

✔

Done

On-going

Implementation- Engineer recruitment✔- Equipment acquisition✔- Installation and

qualification of the equipments✔

- Technical validations

Riskanalysis✔

Product Definition- Technology✔- Standard ✔-

2424

25

+ 8% in revenues versus FY 2015 Growth in clinical genomics (Gustave Roussy and Pasteur) +30% versus 2015

GECO (Genomic Consulting) launched in Q2 2015

Revenues on R&D segment stable after price erosion in 2015

2016 results to be communicated on April 7, 2017

26

Stock price : 3,35 €

# stock units : 5 070 322

# of options : 772 000

Market cap : 17 M€

Eligible PEA-PMEAverage volume - 1 month 31 681

Average volume - 3 months 21 716

Average volume - 6 months 23 963

BIOAM 12.9%

Other historic 8,2%

Other

IDINVEST 12,4%

27

IntegraGen Confidential

In millions of euros 2015 2014 Var. %

Revenues 5 584 6 036 (7%)

Operating subsidies and other

revenues269 138 ns

Total Revenues 5 853 6 174 (5%)

Operating costs (8 170) (7 875) (4%)

Operating profit (2 317) (1 701) (36%)

Financial Profit/Loss (91) 284 n/a

Exceptional Profit/Loss 549 (91) n/a

Taxes (CIR) 326 464 (30%)

Net result (1 533) (1 044) (47%)

2015 financial highlights

Very low net cash consumption, € 0,2 m

Strong cash position as of Dec 31st : € 5.0 million

Slight decrease in revenues : € 0.3 m (-5%)

Strong growth in clinical genomic services

Pricing pressure on the R & D segment

Cost control continuing to progress while financing important developments

Establishment of a financing line with SociétéGénérale: 100,000 warrants exercised in July (2% of the capital)

28

KEY INDICATORS - in thousand €S1 2016

(6 mois)

S1 2015 (6 mois)

Var. %

Sales 2 880 2 624 + 10%

Total revenues 3 034 2 678 + 13%

Operational results - 1 152 - 1 343 + 14%

Net result - 1 028 - 872 - 18%

2929

30

Grow of partnerships in clinical genomics • Access new clinical genomic platforms as the sole or partner operator

Enlarge digital genomics offering

• Continue development of clinical sequencing offers such as circulating tumor exome, low DNA quantity

• Develop & market bio-informatics software• Grow GeCo expertise and IT support

Launch miRpredX diagnostic kit in Europe, achieve industrial partnerships • Licensing partners in North America and in Europe

Select R&D partnerships• Access to clinical trials relevant for miR-31-3p biomarker in Colorectal and Lund cancer

• Companion Dx agreement

31